Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MI, USA.
Department of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Curr Gastroenterol Rep. 2021 Mar 23;23(3):4. doi: 10.1007/s11894-021-00806-5.
People with cystic fibrosis (CF) are living longer. General age-related and CF-specific gastrointestinal symptoms are increasingly recognized. In this article, we review the latest data on luminal gastrointestinal manifestations in CF.
People with CF have increased incidence of gastroesophageal reflux disease symptoms and often prescribed proton-pump inhibitors (PPI). PPI use may increase risk of pulmonary exacerbations. Evidence to support gastric fundoplication to improve pulmonary outcomes is limited. Features of intestinal dysmotility are common. There are distinct differences in the gut microbiome in the CF population which may have clinical implications. CF is a possible hereditary digestive cancer syndrome, particularly in regard to colorectal cancer (CRC) with earlier incidence of CRC and advanced colonic neoplasia. Early screening colonoscopy is warranted in the CF population. Gastrointestinal manifestations in CF are prevalent across all digestive organs. More study on the effect of interventions for symptomatic treatment and cancer screening is needed.
囊性纤维化 (CF) 患者的寿命越来越长。人们越来越认识到与年龄相关的一般和 CF 特异性胃肠道症状。本文综述了 CF 腔内胃肠道表现的最新数据。
CF 患者胃食管反流病症状的发生率增加，经常开质子泵抑制剂 (PPI)。PPI 的使用可能会增加肺部恶化的风险。支持胃底折叠术改善肺部结果的证据有限。肠道动力障碍的特征很常见。CF 人群的肠道微生物组存在明显差异，这可能具有临床意义。CF 可能是一种遗传性消化癌综合征，特别是在结直肠癌 (CRC) 方面，CRC 的发病率更早，结肠高级别瘤变更常见。CF 人群需要进行早期筛查结肠镜检查。CF 患者的胃肠道表现普遍存在于所有消化器官中。需要更多的研究来干预症状治疗和癌症筛查。
